Navigation Links
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
Date:6/23/2008

MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA. The oral platform abstract presentation, "Inhaled Loxapine, a Dopamine Antagonist, Reduces Headache Pain in Patients Having an Acute Migraine Attack", is scheduled for Friday, June 27, 2008 at 10:55 a.m. Eastern Time, and will be presented in University Hall. AZ-104 is a lower dose version of AZ-004, which is in Phase 3 clinical development for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated scientific presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward- looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in the poster presentation are made as of their date of presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
2. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
10. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
11. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 bioLytical Laboratories, un líder mundial en test rápidos ... HIV Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la ...
(Date:12/2/2016)... DUBLIN , Dec 2, 2016 Research ... Market Size, Share, Development, Growth and Demand Forecast to 2022" report ... , , ... revenue of $6 billion in 2015, and it is expected to grow ... ultrasound segment is expected to witness faster growth during the forecast period, ...
(Date:12/2/2016)... , December 2, 2016 On ... Committee honored excellence in research, development and innovation in ... gala dinner was held in the presence of Sergey ... Russian Federation , Natalia Sanina, First ... Mikhail Murashko , Head of Roszdravnadzor, National Service of ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... needy individuals and families from eight different sites throughout Miami-Dade and Broward counties. ... 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual meals ...
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the mixture of ... my teeth," said an inventor from Bridgewater, N.J. "I thought that there had to ... device." , He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... treatment has announced the opening of a new residential mental health treatment program ... mental health issues such as severe anxiety, depression, bi-polar disorder, and other related ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Clinical ... that the FDA Binding Guidance goes into effect next month. Sponsors whose studies ... the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies the ...
Breaking Medicine News(10 mins):